New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 5, 2014
06:58 EDTBCRXBioCryst reports Q2 EPS (23c), consensus (19c)
Reports Q2 revenue $1.47M, consensus $2.32M.
News For BCRX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
September 1, 2015
10:51 EDTBCRXBioCryst, ASPR/BARDA amend agreement for development of BCX4430
BioCryst Pharmaceuticals said in a regulatory filing that on August 28, the company and the Biomedical Advanced Research and Development Authority within the U.S. Department of Health and Human Services' Office of the Assistant Secretary for Preparedness and Response amended the Agreement dated March 27 for the continued development of BCX4430 as a potential treatment for diseases caused by RNA pathogens, including filoviruses. Pursuant to this amendment, ASPR/BARDA exercised an option under the Agreement to authorize $4.2M of funding to enable non-clinical NDA-enabling toxicology studies and obligated an additional $1.2M of new funding to support previously authorized drug substance and drug product cGMP manufacturing by U.S. suppliers for non-clinical and clinical activities. The execution of the Amendment represents an additional $5.4M in funding BioCryst to support BCX4430 drug manufacturing and toxicology studies, and increases the total potential value of the contract to $36.2M. The period of performance under the exercised options extends through April 14, 2017, while the period of performance under the base period of the contract remains unchanged, extending through September 30, 2016.

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use